Trial · NCT06382987
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
NCT06382987, Recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect). Trials, record NCT06382987. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06382987
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- NCT number
- NCT06382987
- Status
- Recruiting
- Enrollment
- 600 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Apremilast
- First posted
- 2024-04-25
- Last updated
- 2024-04-25
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib or apremilast | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants treated with deucravacitinib with a change in Physician's Global Assessment (PGA) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants treated with deucravacitinib with a change in Dermatology Life Quality Index (DLQI) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06382987
GET https://conductscience.org/api/trials/v1/NCT06382987/registered